NRAS and neoplasm: As we already suggested earlier, a subset of patients (showing gene mutations in PIK3CA, HRAS, KRAS, NRAS and BRAF or ALK translocation) could benefit from a systemic treatment with a PI3K, MEK, BRAF or ALK inhibitor in the case of unresectable or metastasized tumor stage [2].